Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Statins for Familial Hypercholesterolemia from Childhood.

Bijl D, Hama R.

N Engl J Med. 2020 Jan 30;382(5):487-488. doi: 10.1056/NEJMc1915311. No abstract available.

PMID:
31995703
2.

Brainstem Posterior Reversible Encephalopathy Syndrome.

Hama R, Oshikawa H.

Intern Med. 2019 Oct 1;58(19):2901-2902. doi: 10.2169/internalmedicine.2784-19. Epub 2019 Jun 7. No abstract available.

3.

Response letter to 'does high LDL-cholesterol cause cardiovascular disease?'

Ravnskov U, De Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Mascitelli L, McCully KS, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

Expert Rev Clin Pharmacol. 2019 Feb;12(2):93-94. doi: 10.1080/17512433.2019.1561102. Epub 2019 Jan 16. No abstract available.

PMID:
30563359
4.

LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature.

Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Mascitelli L, McCully KS, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

Expert Rev Clin Pharmacol. 2018 Oct;11(10):959-970. doi: 10.1080/17512433.2018.1519391. Epub 2018 Oct 11. Review.

PMID:
30198808
5.

A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017.

Okuyama H, Hamazaki T, Hama R, Ogushi Y, Kobayashi T, Ohara N, Uchino H.

Pharmacology. 2018;101(3-4):184-218. doi: 10.1159/000486374. Epub 2018 Jan 19. Review.

6.

The mechanisms of sudden-onset type adverse reactions to oseltamivir.

Hama R, Bennett CL.

Acta Neurol Scand. 2017 Feb;135(2):148-160. doi: 10.1111/ane.12629. Epub 2016 Jun 30. Review.

7.

Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review.

Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, Kendrick M, Langsjoen PH, Malhotra A, Mascitelli L, McCully KS, Ogushi Y, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R.

BMJ Open. 2016 Jun 12;6(6):e010401. doi: 10.1136/bmjopen-2015-010401. Review.

8.

The mechanisms of delayed onset type adverse reactions to oseltamivir.

Hama R.

Infect Dis (Lond). 2016 Sep;48(9):651-60. doi: 10.1080/23744235.2016.1189592. Epub 2016 Jun 2.

9.

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.

Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T.

Health Technol Assess. 2016 May;20(42):1-242. doi: 10.3310/hta20420. Review.

10.

Oseltamivir for influenza.

Jones M, Hama R, Del Mar C.

Lancet. 2015 Sep 19;386(9999):1133-4. doi: 10.1016/S0140-6736(15)00200-7. No abstract available.

PMID:
26461897
11.

Towards a Paradigm Shift in Cholesterol Treatment. A Re-examination of the Cholesterol Issue in Japan.

Hamazaki T, Okuyama H, Ogushi Y, Hama R.

Ann Nutr Metab. 2015;66 Suppl 4:1-116. doi: 10.1159/000381654. Epub 2015 Apr 29. No abstract available.

12.

Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey.

Takahashi-Ando N, Jones MA, Fujisawa S, Hama R.

Drug Healthc Patient Saf. 2015 Apr 7;7:57-62. doi: 10.2147/DHPS.S78016. eCollection 2015.

13.

Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms.

Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H.

Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99. doi: 10.1586/17512433.2015.1011125. Epub 2015 Feb 6. Erratum in: Expert Rev Clin Pharmacol. 2015;8(4):503-5.

PMID:
25655639
14.

Neuraminidase inhibitors for influenza complications.

Del Mar C, Doshi P, Hama R, Jones M, Jefferson T, Heneghan C, Onakpoya I, Howick J.

Lancet. 2014 Oct 4;384(9950):1260-1. doi: 10.1016/S0140-6736(14)61761-X. No abstract available.

PMID:
25283565
15.

Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Onakpoya I, Heneghan CJ.

BMJ Open. 2014 Sep 30;4(9):e005253. doi: 10.1136/bmjopen-2014-005253.

16.

Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.

Jones M, Del Mar C, Hama R.

Lancet Respir Med. 2014 Jul;2(7):e9-e10. doi: 10.1016/S2213-2600(14)70126-2. Epub 2014 Jun 16. No abstract available.

PMID:
24948431
17.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ.

Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965. doi: 10.1002/14651858.CD008965.pub4. Review.

18.

Cholesterol issues in Japan--why are the goals of cholesterol levels set so low?

Hamazaki T, Okuyama H, Ogushi Y, Hama R.

Ann Nutr Metab. 2013;62(1):32-6. doi: 10.1159/000342765. Epub 2012 Dec 4. No abstract available.

19.

Neuropsychiatric adverse events and oseltamivir for prophylaxis.

Jones M, Hama R, Jefferson T, Doshi P.

Drug Saf. 2012 Dec 1;35(12):1187-8; author reply 1188-90. doi: 10.2165/11641690-000000000-00000. No abstract available.

PMID:
23137156
20.

Antivirals for treatment of influenza.

Jones MA, Hama R, Del Mar C.

Ann Intern Med. 2012 Sep 4;157(5):385; author reply 386-7. doi: 10.7326/0003-4819-157-5-201209040-00016. No abstract available.

PMID:
22944881
21.

Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.

Hama R, Watanabe Y, Shinada K, Yamada Y, Ogata Y, Yoshida Y, Tamura T, Hiraishi T, Oikawa R, Sakurai J, Maehata T, Koizumi H, Itoh F.

Tumour Biol. 2012 Dec;33(6):2031-40. doi: 10.1007/s13277-012-0462-8. Epub 2012 Jul 27.

PMID:
22836805
22.

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965. doi: 10.1002/14651858.CD008965.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;4:CD008965.

PMID:
22258996
23.

Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza.

Hama R, Jones M, Okushima H, Kitao M, Noda N, Hayashi K, Sakaguchi K.

Int J Risk Saf Med. 2011;23(4):201-15. doi: 10.3233/JRS-2011-0545.

PMID:
22156085
24.

A/H1N1 flu. NSAIDs and flu.

Hama R.

BMJ. 2009 Jun 15;338:b2345. doi: 10.1136/bmj.b2345. No abstract available.

PMID:
19528116
25.
26.

Effects of itopride hydrochloride on the delayed rectifier K+ and L-type CA2+ currents in guinea-pig ventricular myocytes.

Morisawa T, Hasegawa J, Hama R, Kitano M, Kishimoto Y, Kawasaki H.

Res Commun Mol Pathol Pharmacol. 1999;106(1-2):37-45.

PMID:
11127807
27.

Drug approval in Japan questioned.

Hayashi K, Hashimoto K, Yanagi M, Umeda T, Hama R.

Lancet. 1998 Aug 8;352(9126):491. No abstract available.

PMID:
9708787
28.

Evaluation of oral anti-allergic drugs in Japan.

Hayashi K, Hama R.

Lancet. 1996 Feb 17;347(8999):477. No abstract available.

PMID:
8618517
29.

Clinical cases and problems of delayed (tardive) reactions to drugs--for pharmaceuticals in general.

Hama R.

J Toxicol Sci. 1996 Feb;21(1):81-91. Review. No abstract available.

30.

Anaphylactic symptoms due to chlorhexidine gluconate.

Okano M, Nomura M, Hata S, Okada N, Sato K, Kitano Y, Tashiro M, Yoshimoto Y, Hama R, Aoki T.

Arch Dermatol. 1989 Jan;125(1):50-2.

PMID:
2910207
31.

High incidence of anaphylactic reactions to cefaclor.

Hama R, Mori K.

Lancet. 1988 Jun 11;1(8598):1331. No abstract available.

PMID:
2897571
32.

Supplemental Content

Support Center